|Recombinant Human IL-6R / CD126 protein (Catalog#10398-H08H)|
|Please contact us for more information.|
|0.2 μm filtered solution in PBS|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-6R / CD126 (rh IL-6R / CD126; Catalog#10398-H08H; NP_000556.1; Met1-Pro365). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
No cross-reactivity with rat IL6R (Catalog # 81072-R02H) , mouse IL6R (Catalog # 50280-M08H) and canine IL6R (Catalog # 70117-D08H) in ELISA assay
This IL6R Neutralizing Antibody can not block the binding of recombinant IL6 (Catalog # 10395-HNAE) to its recombinant receptor IL6 Rα (Catalog # 10398-H08H) .
The neutralization activity of IL6R Neutralizing Antibody is measured by its ability to neutralize IL6 Rα-mediated inhibition of proliferation in the M1 mouse myeloid leukemia cell line. The Neutralization Titer (IC50) is typically 0.15-0.6 µg/mL in the presence of 50 ng/mL Recombinant Human IL6 Rα (Catalog # 10398-H08H) and 100 ng/mL Recombinant Human IL6 (Catalog # 10395-HNAE) .
Interleukin 6 receptor (IL-6R) also known as CD126 (Cluster of Differentiation 126) is a type I cytokine receptor. The low concentration of a soluble form of IL-6 receptor (sIL-6R) acts as an agonist of IL-6 activity. In the IL-6R/CD126/IL6R system, both a membrane-bound IL-6R and a sIL-6R protein are able to mediate IL-6 signals into the cells through the interaction of gp130. The resulting IL-6/sIL-6R protein complex is also capable of binding to gp130 and inducing intracellular signalling. Through this so-called 'trans-signalling' mechanism, IL-6 is able to stimulate cells that lack an endogenous mIL-6R. High levels of IL-6 and sIL-6R have been reported in several chronic inflammatory and autoimmune diseases as well as in cancer.